Brought to you by 
CRISPR nets $107mm through public offering
09 Jan 2018
Executive Summary
CRISPR Therapeutics AG (gene editing) netted $107mm through a public offering of 5mm common shares at $22.75. Funds will support continued development of pipeline projects including CTX001 for beta thalassemia and sickle cell disease and CTX101, an immunotherapy for CD19-positive cancers.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
-
Drug Discovery Tools
- Genomics-Proteomics
Deal Status
- Final
Deal Type
-
Financing
- FOPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
CRISPR nets $107mm through public offering
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice